Cumulus Neuroscience présente, lors du congrès annuel de l'AAIC 2026, des données montrant qu'une tâche numérique de deux minutes atteint ou dépasse les critères de référence cliniques en matière de pré-sélection des participants à un essai clinique sur la maladie d'Alzheimer.
Summary
Cumulus Neuroscience presented data at AAIC 2026 showing its two-minute Symbol Swap digital task on the NeuLogiq platform meets or exceeds clinical benchmarks for pre-screening Alzheimer's disease trial participants. The results were validated across three independent studies demonstrating significant differentiation between controls, mild cognitive impairment, and disease groups.
Clinical Trial Data
Met
Outcome Details
Two-minute digital task on NeuLogiq platform achieved or exceeded clinical reference criteria for pre-screening Alzheimer's disease trial participants across three independent studies, showing clinically significant distinction between control groups, mild cognitive impairment (MCI), and disease groups
Read the original article
Published by PR Newswire Biotech on July 15, 2026 1:54 PM